Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer

Wang, Bi-Dar and Ceniccola, Kristin and Hwang, SuJin and Andrawis, Ramez and Horvath, Anelia and Freedman, Jennifer A. and Olender, Jacqueline and Knapp, Stefan and Ching, Travers and Garmire, Lana and Patel, Vyomesh and Garcia-Blanco, Mariano A. and Patierno, Steven R. and Lee, Norman H. (2017) Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nature Communications, 8. 15921. ISSN 2041-1723 (https://doi.org/10.1038/ncomms15921)

[thumbnail of Wang-etal-NC-2017-Alternative-splicing-promotes-tumour-aggressiveness]
Preview
 Text. Filename: Wang_etal_NC_2017_Alternative_splicing_promotes_tumour_aggressiveness.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Clinical challenges exist in reducing prostate cancer (PCa) disparities. The RNA splicing landscape of PCa across racial populations has not been fully explored as a potential molecular mechanism contributing to race-related tumour aggressiveness. Here, we identify novel genome-wide, race-specific RNA splicing events as critical drivers of PCa aggressiveness and therapeutic resistance in African American (AA) men. AA-enriched splice variants of PIK3CD, FGFR3, TSC2 and RASGRP2 contribute to greater oncogenic potential compared with corresponding European American (EA)-expressing variants. Ectopic overexpression of the newly cloned AA-enriched variant, PIK3CD-S, in EA PCa cell lines enhances AKT/mTOR signalling and increases proliferative and invasive capacity in vitro and confers resistance to selective PI3Kδ inhibitor, CAL-101 (idelalisib), in mouse xenograft models. High PIK3CD-S expression in PCa specimens associates with poor survival. These results highlight the potential of RNA splice variants to serve as novel biomarkers and molecular targets for developmental therapeutics in aggressive PCa.

CORE (COnnecting REpositories)